1832 Asset Management
TRIL

1832 Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

1832 Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,500
Closed -$14K – 736
2018
Q2 		$14K Hold
2,500
– – ﹤0.01% 562
2018
Q1 		$18K Hold
2,500
– – ﹤0.01% 576
2017
Q4 		$18K Buy
+2,500
New +$20.7K ﹤0.01% 592
2017
Q3 		– Sell
-2,500
Closed -$11K – 763
2017
Q2 		$11K Hold
2,500
– – ﹤0.01% 605
2017
Q1 		$15K Buy
+2,500
New +$14.7K ﹤0.01% 637

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

1832 Asset Management's TRIL Position: Q3 2018 in Review

1832 Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2018, closing a stake of 2,500 shares — an estimated $14K sold.

1832 Asset Management first reported a position in TRIL in Q1 2017 and held it in 5 quarters. The position peaked at $18K in Q1 2018. 26 funds tracked by Wall St. Rank hold TRIL as of Q3 2018.

  • 1832 Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2018 after selling out during the quarter.
  • 1832 Asset Management sold 2,500 Trillium Therapeutics Inc. shares in Q3 2018, an estimated $14K.
  • 1832 Asset Management first reported a position in Trillium Therapeutics Inc. in Q1 2017 and held it in 5 quarters.
  • 1832 Asset Management's Trillium Therapeutics Inc. position peaked at $18K in Q1 2018.
  • 26 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2018.

Based on 1832 Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.